Expert Review of Neurotherapeutics最新文献_第3页

Advances in stem cell-based therapeutic transfers for glioblastoma treatment. 干细胞转移治疗胶质母细胞瘤的研究进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-21 DOI: 10.1080/14737175.2025.2490543

Mainak Bardhan, Muneeb Ahmad Muneer, Abhinav Khare, Rushita Minesh Shah, Anmol Kaur, Sonit Sai Vasipalli, Vinay Suresh, Vivek Podder, Manmeet Ahluwalia, Yazmin Odia, Zhijian Chen

{"title":"Advances in stem cell-based therapeutic transfers for glioblastoma treatment.","authors":"Mainak Bardhan, Muneeb Ahmad Muneer, Abhinav Khare, Rushita Minesh Shah, Anmol Kaur, Sonit Sai Vasipalli, Vinay Suresh, Vivek Podder, Manmeet Ahluwalia, Yazmin Odia, Zhijian Chen","doi":"10.1080/14737175.2025.2490543","DOIUrl":"https://doi.org/10.1080/14737175.2025.2490543","url":null,"abstract":"Introduction: Glioblastoma (GBM), a highly malignant brain tumor, has a poor prognosis despite standard treatments like surgery, chemotherapy, and radiation. Glioblastoma stem cells (GSCs) play a critical role in recurrence and therapy resistance. Stem cell-based therapies have emerged as innovative approaches, leveraging the tumor-targeting abilities of stem cells to deliver treatments directly to GBM.Areas covered: This review focuses on using intact stem cells or subtypes for GBM therapy, excluding antigenic characteristics. The stem cell-based therapies explored include neural, mesenchymal, glioblastoma, hematopoietic and adipose-derived stem cells that have been investigated in both clinical and preclinical settings. A systematic search in PubMed, EMBASE, ClinicalTrials.gov, and Scopus had identified research up until January 2024. Key mechanisms reviewed include immune modulation, angiogenesis inhibition, and apoptosis induction. Discussion of completed and ongoing trials include emphasis on safety, efficacy, challenges, and study design limitations.Expert opinion: Stem cell-based therapies hold promise for treating GBM by targeting GSCs and improving treatment outcomes. Despite some potential advantages, challenges such as tumorigenesis risks, delivery complexities, and sustained therapeutic effects persist. Future research should prioritize optimizing stem cell modifications, combining them with current treatments, and conducting large-scale trials to ensure safety and efficacy. Integrating stem cell therapies into GBM treatment could provide more effective and less invasive options for patients.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-17"},"PeriodicalIF":3.4,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the challenges with the differential diagnosis of schizotypal personality disorder. 精神分裂型人格障碍鉴别诊断的挑战概述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-17 DOI: 10.1080/14737175.2025.2492379

Katherine V Raffensperger, Philip D Harvey

{"title":"An overview of the challenges with the differential diagnosis of schizotypal personality disorder.","authors":"Katherine V Raffensperger, Philip D Harvey","doi":"10.1080/14737175.2025.2492379","DOIUrl":"https://doi.org/10.1080/14737175.2025.2492379","url":null,"abstract":"Introduction: Schizotypal personality disorder (SPD) has a long history, and there is still considerable ongoing research. Although there are overlapping features of SPD and other personality disorders, the full constellation of schizotypal features is broader. The longitudinal course of SPD is variable, with differences in trajectory manifesting lifelong clinical significance. Particularly important is the relationship between SPD and prodromal states that may result in an eventual diagnosis of psychosis.Areas covered: This review covers the history and differential diagnosis of SPD, including the older conceptualization of 'borderline schizophrenia.' Clinical, cognitive, functional, brain imaging, and genetic features of SPD, and the implications of age at onset and method of ascertainment of the condition are reviewed. Differences between psychometrically identified schizotypy, clinically diagnosed SPD, and other psychiatric conditions are described. A comprehensive literature search using MEDLINE (via PubMed) did not specify a date range, to capture the full scope of research.Expert opinion: SPD is unique in that the age at ascertainment is critical for the persistence of the diagnosis. When diagnosed with SPD in late adolescence, some individuals develop psychosis, some remit, and others have persistent, lifelong symptoms. Predictors of conversion to psychosis have been identified but are no proven treatments.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The differential diagnosis of autism spectrum disorder in adults. 成人自闭症谱系障碍的鉴别诊断。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-13 DOI: 10.1080/14737175.2025.2490533

Hannah M Carroll, Robyn P Thom, Christopher J McDougle

{"title":"The differential diagnosis of autism spectrum disorder in adults.","authors":"Hannah M Carroll, Robyn P Thom, Christopher J McDougle","doi":"10.1080/14737175.2025.2490533","DOIUrl":"10.1080/14737175.2025.2490533","url":null,"abstract":"Introduction: Diagnosing autism spectrum disorder (ASD) in adults is challenging due to its heterogeneity and symptom overlap with other conditions. Making an accurate diagnosis can be difficult and overwhelming but is vital for proper accommodations and interventions while avoiding unproductive or harmful treatments.Areas covered: The authors have based their review on a comprehensive literature search using PubMed, PsycINFO, and Google Scholar to identify relevant recommendations, diagnostic tools, and common differential diagnoses for adults with ASD. A clinical framework is provided based on the DSM-5 criteria, starting with an evaluation of childhood symptom onset and persistent manifestations of the core criteria - social and communication impairment, along with restricted, repetitive behaviors. Conditions with overlapping presentations, including personality disorders, anxiety, depression, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, and schizophrenia, are discussed, as well as challenges in differentiating these from ASD.Expert opinion: Many factors complicate diagnosing ASD in adults - such as skewed public perception or misinformation spread on social media. Existing tools frequently miss subtle or atypical presentations, particularly in underdiagnosed groups like women and older adults. Promising advances in machine learning and artificial intelligence will hopefully improve diagnostic precision in the future. Up-to-date clinician training and large-scale research remain paramount for refining adult ASD diagnosis.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-14"},"PeriodicalIF":3.4,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in endovascular thrombectomy for the treatment of acute ischemic stroke. 血管内取栓治疗急性缺血性脑卒中的研究进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-13 DOI: 10.1080/14737175.2025.2490538

David Lauer, Jakub Sulženko, Hana Malíková, Ivana Štětkářová, Petr Widimský

{"title":"Advances in endovascular thrombectomy for the treatment of acute ischemic stroke.","authors":"David Lauer, Jakub Sulženko, Hana Malíková, Ivana Štětkářová, Petr Widimský","doi":"10.1080/14737175.2025.2490538","DOIUrl":"10.1080/14737175.2025.2490538","url":null,"abstract":"Introduction: Acute ischemic stroke (AIS) is the second leading cause of death and one of the leading causes of long-term disability globally. Endovascular thrombectomy (EVT) has revolutionized treatment for large vessel occlusion (LVO), providing 20% increase in post-stroke functional independence compared to intravenous thrombolysis (IVT) alone. Despite its proven efficacy, EVT is underutilized. While it is suitable for at least 15-20% of AIS patients, its mean adoption ranges from less than 1% to 7% in different areas.Areas covered: This review highlights key findings from pivotal randomized controlled trials and real-world data, focusing on patient selection criteria, advancements in thrombectomy devices, and procedural innovations. A comprehensive literature search was performed using PubMed, Scopus, EMBASE and the Cochrane Library for relevant randomized controlled trials and observational studies.Expert opinion: Disparity in access to EVT requires strategic investments in healthcare systems and international multidisciplinary collaboration. Enhancing geographic coverage with thrombectomy-capable centers and optimizing prehospital triage systems are essential. Bridging the gap between treatment capability and real-world implementation is critical to improving global AIS outcomes.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-13"},"PeriodicalIF":3.4,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation between systemic bleeding during thrombolysis and intracranial hemorrhage after thrombolysis in acute ischemic stroke. 急性缺血性脑卒中溶栓时全身性出血与溶栓后颅内出血的相关性。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-10 DOI: 10.1080/14737175.2025.2491674

Xin-Lei Mao, Si-Si He, Ya-Xi Zhang, Cai-Dan Lin, Xin-Xin Chen, Shi-Zheng Zhang, Li-Na Ge, Qing-Qing Zhuang

{"title":"Correlation between systemic bleeding during thrombolysis and intracranial hemorrhage after thrombolysis in acute ischemic stroke.","authors":"Xin-Lei Mao, Si-Si He, Ya-Xi Zhang, Cai-Dan Lin, Xin-Xin Chen, Shi-Zheng Zhang, Li-Na Ge, Qing-Qing Zhuang","doi":"10.1080/14737175.2025.2491674","DOIUrl":"https://doi.org/10.1080/14737175.2025.2491674","url":null,"abstract":"Background: Current models primarily predict outcomes before thrombolytic therapy. This study explored if systemic bleeding during thrombolysis predicts hemorrhagic transformation (HT) within 36 hours post-thrombolysis.Research design and methods: Data from 591 acute ischemic stroke patients treated with rt-PA at Wenzhou Central Hospital (2016-2023) were prospectively collected and analyzed. The incidence of systemic bleeding was compared with the Stroke Prognostication using Age and the National Institutes of Health Stroke Scale (Span100) index, as well as the Hemorrhage After Thrombolysis (HAT) scale.Results: Systemic bleeding occurred in 285 patients, including 92 with HT. The HT rate was significantly higher in patients with late-onset oral bleeding (35.90%) or other systemic bleeding (38.89%) than in those without (p < 0.01). Late-onset oral and systemic bleeding during thrombolysis predicted HT in anterior circulation infarction (p < 0.001) but not in posterior circulation infarction (p = 0.70). The AUC for predicting HT was 0.578 for these bleeding types, versus 0.568 for Span-100 and 0.61 for HAT. Incorporating bleeding types increased Span-100 sensitivity to 0.623 and HAT to 0.648.Conclusions: Late-onset oral and other systemic bleeding during thrombolysis effectively predict HT in anterior circulation infarction, enhancing the sensitivity of Span100 and HAT scales when combined.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the potential of virtual reality for post-stroke sensorimotor rehabilitation - are we any closer? 释放虚拟现实在中风后感觉运动康复中的潜力——我们离目标更近了吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-08 DOI: 10.1080/14737175.2025.2490535

Mindy F Levin, Jeroen B J Smeets

引用次数: 0

The utility of magnetoencephalography in epilepsy and its implications for treatment. 脑磁图在癫痫中的应用及其治疗意义。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-02-22 DOI: 10.1080/14737175.2025.2470333

Samuel Molot-Toker, James T Rutka, Eisha Christian

引用次数: 0

Charcot-Marie-Tooth disease: a review of clinical developments and its management - What's new in 2025? 乳齿赘肉病：临床发展及其管理综述——2025年有什么新发现？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-03-07 DOI: 10.1080/14737175.2025.2470980

Amedeo De Grado, Marina Serio, Paola Saveri, Chiara Pisciotta, Davide Pareyson

{"title":"Charcot-Marie-Tooth disease: a review of clinical developments and its management - What's new in 2025?","authors":"Amedeo De Grado, Marina Serio, Paola Saveri, Chiara Pisciotta, Davide Pareyson","doi":"10.1080/14737175.2025.2470980","DOIUrl":"10.1080/14737175.2025.2470980","url":null,"abstract":"Introduction: Charcot-Marie-Tooth disease (CMT) understanding and diagnostic rates are improving. Symptomatic management is still the only option, but many therapeutic approaches are under investigation, some in the clinical trial phase.Areas covered: Through a comprehensive search in PubMed, the ClinicalTrials.gov website, and the latest abstracts on the topic, the authors review the diagnostic advances and promising treatments, focusing on pharmacological and gene therapy/silencing approaches, and on clinical trial challenges. They also review current CMT management, including rehabilitation, orthotics, and associated symptoms and comorbidities.Expert opinion: The CMT field is evolving rapidly, with significant advances in genetic diagnosis and disease recognition. International networks and patient organization partnerships are vital for progress, enabling collaboration and large-scale studies. Metabolic neuropathies are relatively easier to target, and interim analysis results from the CMT-SORD trial suggest govorestat may become the first approved CMT drug. Gene therapy shows promise but currently faces safety and targeting challenges; PMP22 silencers for CMT1A are close to being tested in patients. New drugs, such as HDAC6 inhibitors, are also approaching the clinical trial phase, despite existing hurdles. Supportive care, including rehabilitation and orthotics, continues to improve quality of life. There is optimism that within the next decade, approved therapies will reduce disease burden.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"427-442"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Laser interstitial thermal therapy for recurrent brain metastases following stereotactic radiosurgery: a systematic review. 激光间质热治疗在立体定向放射手术后复发性脑转移瘤：系统回顾。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-02-27 DOI: 10.1080/14737175.2025.2471551

Timoteo Almeida, Jheremy S Reyes, Sydney E Scanlon, Stephen C Frederico, Sakibul Huq, Costas G Hadjipanayis

{"title":"Laser interstitial thermal therapy for recurrent brain metastases following stereotactic radiosurgery: a systematic review.","authors":"Timoteo Almeida, Jheremy S Reyes, Sydney E Scanlon, Stephen C Frederico, Sakibul Huq, Costas G Hadjipanayis","doi":"10.1080/14737175.2025.2471551","DOIUrl":"10.1080/14737175.2025.2471551","url":null,"abstract":"Introduction: Laser Interstitial Thermal Therapy (LITT) has emerged as a promising minimally invasive treatment option for recurrent brain metastases, especially for patients who have previously undergone Stereotactic Radiosurgery (SRS). Despite its growing use, additional research is needed to explore its utility and safety in this population.Methods: This systematic review evaluates the literature on LITT for recurrent brain metastases post-SRS, including patient selection, treatment protocols, outcomes, and complications. The review was registered with PROSPERO (CRD42024577899) and followed the PRISMA 2020 guidelines.Results: Seventeen studies, encompassing 694 patients, met our inclusion criteria. The median overall survival (OS) across these studies was 14.4 months with an average 12-month OS of 60.1%. Notably, median OS was 5.9 months after LITT alone and 12.7 months when LITT was followed by adjuvant SRS. The pooled local control rate was 75.6% at 6 months and 72.2% at 12 months.Conclusion: LITT is a minimally invasive treatment option that has shown potential in managing recurrent brain metastases after prior SRS, particularly when biopsy is required to differentiate between tumor recurrence and radiation necrosis. However, data on the comparative efficacy and cost-effectiveness of LITT versus alternative treatments such as repeat SRS or craniotomy remain limited.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"465-475"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive update on neuroimaging endpoints in amyotrophic lateral sclerosis. 肌萎缩性侧索硬化症神经影像学终点的全面更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-03-12 DOI: 10.1080/14737175.2025.2470324

Massimo Filippi, Alma Ghirelli, Edoardo Gioele Spinelli, Federica Agosta

{"title":"A comprehensive update on neuroimaging endpoints in amyotrophic lateral sclerosis.","authors":"Massimo Filippi, Alma Ghirelli, Edoardo Gioele Spinelli, Federica Agosta","doi":"10.1080/14737175.2025.2470324","DOIUrl":"10.1080/14737175.2025.2470324","url":null,"abstract":"Introduction: There are currently few treatments approved for amyotrophic lateral sclerosis (ALS). Additionally, there remains a significant unmet need for reliable, standardized biomarkers to assess endpoints in clinical trials. Magnetic resonance imaging (MRI)- and positron emission tomography (PET)-derived metrics could help in patient selection and stratification, shortening trial duration and reducing costs.Areas covered: This review focuses on the potential use of neuroimaging endpoints in the context of ALS therapeutic trials, providing insights on structural and functional neuroimaging, plexus and muscle alterations, glial involvement and neuroinflammation, envisioning how these surrogates of disease progression could be implemented in clinical trials. A PubMed search covering the past 15 years was performed.Expert opinion: Neuroimaging is essential in understanding ALS pathophysiology, aiding in disease progression tracking and evaluating therapeutic interventions. High costs, limited accessibility, lack of standardization, and patient tolerability limit their use in routine ALS care. Addressing these obstacles is essential for fully harnessing neuroimaging potential in improving diagnostics and treatment in ALS.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"397-413"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0